VERTEX PHARMACEUTICALS INC / MA Research and Development Asset Acquired Other than Through Business Combination, Written-off
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $21.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $21.40M, a 872.73% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $500.00K, a 97.47% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $56.50M, a 35.43% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $54.50M, a 263.33% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for fiscal 2025 was $133.00M, a 97.13% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for fiscal 2024 was $4.63B, a 778.09% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for fiscal 2023 was $527.10M, a 356.36% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA research and development asset acquired other than through business combination, written-off for fiscal 2022 was $115.50M, a 89.63% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.40M 10-Q · filed 2026-08-04 | $21.90M 10-Q · filed 2026-08-04 | $78.40M derived: sum of 3 quarters · filed 2026-08-04 | $132.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-05 | $57.00M derived: sum of 2 quarters · filed 2026-05-05 | $111.50M derived: sum of 3 quarters · filed 2026-05-05 | $113.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $56.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $111.00M derived: sum of 2 quarters · filed 2026-02-13 | $113.20M derived: sum of 3 quarters · filed 2026-08-04 | $133.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $54.50M 10-Q · filed 2025-11-04 | $56.70M derived: sum of 2 quarters · filed 2026-08-04 | $76.50M 10-Q · filed 2025-11-04 | $164.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $2.20M 10-Q · filed 2026-08-04 | $22.00M 10-Q · filed 2026-08-04 | $109.50M derived: sum of 3 quarters · filed 2026-08-04 | $124.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $19.80M 10-Q · filed 2026-05-05 | $107.30M derived: sum of 2 quarters · filed 2026-05-05 | $122.30M derived: sum of 3 quarters · filed 2026-05-05 | $4.57B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $87.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $102.50M derived: sum of 2 quarters · filed 2026-02-13 | $4.55B derived: sum of 3 quarters · filed 2026-02-13 | $4.63B 10-K · filed 2026-02-13 |
| 2024-09-30 | $15.00M 10-Q · filed 2025-11-04 | $4.46B derived: sum of 2 quarters · filed 2025-11-04 | $4.54B 10-Q · filed 2025-11-04 | $4.56B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $4.45B 10-Q · filed 2025-08-05 | $4.53B 10-Q · filed 2025-08-05 | $4.54B derived: sum of 3 quarters · filed 2026-02-13 | $4.60B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $76.80M 10-Q · filed 2025-05-06 | $94.60M derived: sum of 2 quarters · filed 2026-02-13 | $146.30M derived: sum of 3 quarters · filed 2026-02-13 | $256.80M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $17.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $69.50M derived: sum of 2 quarters · filed 2026-02-13 | $180.00M derived: sum of 3 quarters · filed 2026-02-13 | $527.10M 10-K · filed 2026-02-13 |
| 2023-09-30 | $51.70M 10-Q · filed 2024-11-05 | $162.20M derived: sum of 2 quarters · filed 2024-11-05 | $509.30M 10-Q · filed 2024-11-05 | $531.90M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $110.50M 10-Q · filed 2024-08-02 | $457.60M 10-Q · filed 2024-08-02 | $480.20M derived: sum of 3 quarters · filed 2025-02-13 | $509.20M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $347.10M 10-Q · filed 2024-05-07 | $369.70M derived: sum of 2 quarters · filed 2025-02-13 | $398.70M derived: sum of 3 quarters · filed 2025-02-13 | $460.60M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $22.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $51.60M derived: sum of 2 quarters · filed 2025-02-13 | $113.50M derived: sum of 3 quarters · filed 2025-02-13 | $115.50M 10-K · filed 2025-02-13 |
| 2022-09-30 | $29.00M 10-Q · filed 2023-11-07 | $90.90M derived: sum of 2 quarters · filed 2023-11-07 | $92.90M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $61.90M 10-Q · filed 2023-08-02 | $63.90M 10-Q · filed 2023-08-02 | ||
| 2021-12-31 | $1.11B 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |